TAKE Solutions acquires Ecron Acunova in Rs 115-cr deal

Company says acquisition would enhance domain expertise & deliver differentiated value to its customers

TAKE Solutions Ltd, Chennai-based technology company with interest in in life sciences, today announced it has entered into definitive agreements to acquire life sciences services player, Ecron Acunova (EA). The company acquires Ecron Acunova in an Rs 115 crore deal.

Ecron Acunova is a life sciences services company delivering pharmaceutical research services to global clients across South East Asia, Central & Nordic Europe and North America. 

Srinivasan H R, vice chairman and managing director, TAKE Solutions said that globally, there is a growing focus on quality, data, analytics and outcomes in the industry, resulting in increased pharma/biotech R&D spending and funding. 

“TAKE & EA’s combined attributes will strengthen our position as a fully integrated differentiated life sciences services provider to large and small global pharmaceutical companies and thereby broaden the addressable market,” said Srinivasan,

In a release the company said this association will enable TAKE add expertise in the areas of Biosimilars, Regenerative Medicine and Diagnostic imaging agents space which are emerging growth areas.

It would help TAKE move the addressable market for its services to $30 billion and will enhance company's presence in Europe and Nordic countries.

TAKE will explore new vistas of the dynamic pharmaceutical, biotechnology, and medical device R&D markets including the areas of biosimilars, regenerative medicine and diagnostic imaging agents, company said in a statement.

“TAKE’s enhanced capabilities will enable it to be an integral part of the fast growing Biosimilars space. As an innovation driven organization, TAKE will also now be able to expand its IPs in Risk Based Monitoring and other solutions aimed at bringing safe, effective, and affordable drugs and devices to market,” said the company.

With this acquisition, TAKE will add audit ready infrastructure in Europe and India, and parts of South Asia to its expanding footprint.

The organisation will also augment its pool of subject matter experts by 30% and life sciences talent by 50%, experience, innovation and domain expertise.  In addition, the Full Service capability along with expanded infrastructure will allow TAKE to service the mid-market as well.